润达医疗 20250827 摘要 润达医疗 2025 年上半年营收同比下降，主要受医疗政策影响，但经营 性现金流保持健康，为 1.54 亿元。公司通过优化业务结构和内部管理， 亏损幅度有所收窄。 集约化区检业务收入同比下降 24%，但自产产品出口收入增长 75%。AI 新业务加速落地，信息化收入约 9,300 万元，其中 AI 相关产 品服务收入约 5,000 万元。 公司推出医生端"良医"和公众端"小慧"AI 产品，覆盖诊前、诊中、 诊后全流程，并与华西医院、齐鲁医院等合作开发专病智能体，已为 100 多家医院提供 AI 解决方案。 AI 业务面临交付能力瓶颈，但市场需求迫切，意向合作医院项目金额约 10 亿元，大型三甲医院交付周期需 3-4 个月，定制化需求导致交付周期 较长。 公司在 ToC 端与美年健康、泰平保险等合作探索院外场景，计划通过与 医院合作，由医生向患者推广 AI 健康管理服务，如与温州医科大学附属 第一医院合作推广体检智能体。 Q&A 润达医疗在 2025 年上半年业绩表现如何？ 2025 年上半年，润达医疗实现营业收入 34.66 亿元，同比下降 16%。归母净 利润为-1.21 亿元 ...

Group 1 - The core point of the article highlights that RunDa Medical has seen a significant decrease in the number of shareholders, with a reduction of 10,501 accounts, representing a decline of 13.82% from March 31 to June 30, 2025 [1][2] - As of June 30, 2025, the average number of shares held per shareholder increased from 7,945 shares to 9,219 shares, while the average market value of shares held per account was 162,800 yuan [1][2] - Compared to the pharmaceutical commercial industry average, RunDa Medical's shareholder count of 65,478 is above the industry average of 40,100, but its average market value per account is below the industry average of 214,000 yuan [1][2] Group 2 - From March 31 to June 30, 2025, RunDa Medical's stock price experienced a decline of 10.85%, coinciding with the reduction in shareholder accounts [1][2] - During the same period, the net outflow of main funds was 283 million yuan, while retail investors saw a net inflow of 366 million yuan [2]

Group 1 - The board of directors of Shanghai RunDa Medical Technology Co., Ltd. held its 24th meeting on August 26, 2025, with all 11 directors present, including independent directors attending via communication [1] - The meeting approved the 2025 semi-annual report and its summary, with a unanimous vote of 11 in favor [2] - A special report on the storage and actual use of raised funds for the first half of 2025 was also approved, reflecting accurate management of the funds [3] Group 2 - The board approved an increase in the estimated amount for daily related party transactions for 2025 due to business development needs, with 9 votes in favor and 2 abstentions [4] - The board decided to cancel the supervisory board and revise the company's articles of association and related systems, transferring the supervisory powers to the audit committee [5] - The board proposed to reappoint Zhonghua Accounting Firm as the financial audit and internal control audit institution for 2025, with unanimous approval [5] - A resolution to convene the first extraordinary general meeting of shareholders in 2025 was also passed, with all directors voting in favor [6]

证券日报网讯 8月26日晚间，润达医疗发布公告称，公司第五届董事会第二十四次会议审议通过了《关 于审议公司2025年半年度报告及摘要的议案》等多项议案。 （文章来源：证券日报） ...

证券日报网讯 8月26日晚间，润达医疗发布公告称，公司第五届监事会第十七次会议审议通过了《关于 审议公司2025年半年度报告及摘要的议案》等。 （文章来源：证券日报） ...

Meeting Information - The company will hold a temporary shareholders' meeting on September 12, 2025, at 1:30 PM [5] - The meeting will take place at the Star Center, 8th Floor, 89 Zhapu Road, Hongkou District, Shanghai [5][8] - Voting will be conducted through both on-site and online methods using the Shanghai Stock Exchange's network voting system [5][4] Voting Procedures - Shareholders can vote via the trading system or the internet voting platform, with specific time slots for each method [4][5] - Shareholders holding multiple accounts can aggregate their voting rights across all accounts [7] - The first voting result will be considered valid if the same voting right is exercised multiple times [7] Attendance and Registration - Only shareholders registered by the close of trading on the equity registration date are eligible to attend the meeting [7] - Registration for attendance must be completed in person, with specific documentation required for both individual and corporate shareholders [7][10] - The registration period is set for September 10, 2025, from 9:30 AM to 11:30 AM and 1:30 PM to 4:00 PM [11] Proxy Voting - Shareholders can appoint a proxy to attend the meeting and vote on their behalf, with specific documentation required for the proxy [7][9] - The proxy must present identification and authorization documents to register for the meeting [7][10]

Core Viewpoint - The document outlines the decision-making procedures for related party transactions of Shanghai RunDa Medical Technology Co., Ltd, aiming to protect the interests of the company and minority shareholders while ensuring compliance with relevant laws and regulations [1]. Summary by Sections Related Party Transactions Definition - Related party transactions refer to the transfer of resources or obligations between the company, its subsidiaries, and related parties, including various forms of financial assistance, asset transactions, and joint investments [1][2]. Identification of Related Parties - Related parties include individuals or entities that directly or indirectly control the company, its directors, senior management, and significant shareholders [2][3]. Board and Shareholder Meeting Procedures - Related directors must abstain from voting on transactions where they have a conflict of interest, and decisions must be made by a majority of non-related directors [4][5]. - Related shareholders must also abstain from voting on relevant transactions, ensuring that their voting rights do not influence the outcome [5][12]. Transaction Approval and Disclosure - Transactions exceeding certain thresholds (e.g., 300,000 yuan for individuals, 3 million yuan for entities) require approval from independent directors and must be disclosed [10][11]. - For transactions above 30 million yuan or 5% of the company's net assets, board approval is required before submission to the shareholders' meeting [11]. Financial Assistance and Guarantees - The company is prohibited from providing financial assistance to related parties, except under specific conditions where equal terms are offered to all shareholders [12][9]. - Guarantees provided to related parties must also follow strict approval processes involving non-related directors and must be disclosed to shareholders [9]. Daily Related Transactions - Daily related transactions must be documented and disclosed, with specific procedures for approval and reporting based on transaction amounts [14][15]. Exemptions from Approval - Certain transactions, such as those providing unilateral benefits to the company without obligations, may be exempt from the usual approval and disclosure requirements [14]. Implementation and Amendments - The decision-making procedures are subject to amendments by the board and will take effect upon approval by the shareholders' meeting [15].

投资者关系管理制度 （二〇二五年八月） 第一章 总 则 上海润达医疗科技股份有限公司 投资者关系管理制度 上海润达医疗科技股份有限公司 第一条 为了加强上海润达医疗科技股份有限公司（以下简称"公司"） 与投资者和潜在投资者（以下简称"投资者"）之间的沟通，促进公司和投资者 关系的良性发展，规范公司投资者关系工作，根据《中华人民共和国公司法》、 《中华人民共和国证券法》、《上市公司投资者关系管理工作指引》、《上海证 券交易所股票上市规则》等法律法规、规范性文件及《上海润达医疗科技股份有 限公司章程》（以下简称"《公司章程》"）的相关规定，结合公司实际情况， 制定本制度。 第二条 投资者关系管理是指公司通过便利股东权利行使、信息披露、互 动交流和诉求处理等工作，加强与投资者及潜在投资者之间的沟通，增进投资者 对公司的了解和认同，以提升公司治理水平和企业整体价值，实现尊重投资者、 回报投资者、保护投资者目的的相关活动。 第三条 投资者关系管理的基本原则是： （一）合规性原则。公司投资者关系管理应当在依法履行信息披露义务的基 础上开展，符合法律、法规、规章及规范性文件、行业规范和自律规则、公司内 部规章制度，以及行业 ...

上海润达医疗科技股份有限公司 董事会秘书工作规则 上海润达医疗科技股份有限公司 董事会秘书工作规则 (二〇二五年八月） 第一章 总 则 第一条 为规范上海润达医疗科技股份有限公司（以下简称"公司"）董 事会秘书的行为，提高公司治理水平，根据《中华人民共和国公司公司法》（以 下简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、 《上海证券交易所股票上市规则》（以下简称"《上市规则》"）及其他有关法 律、法规规定和《上海润达医疗科技股份有限公司章程》(以下简称"《公司章 程》")制定。 第二条 公司设董事会秘书一名。董事会秘书为公司的高级管理人员，对 公司和董事会负责，忠实、勤勉地履行职责。 第三条 董事会秘书是公司与上海证券交易所之间的指定联络人，负责以 公司名义办理信息披露、公司治理、股权管理等相关职责范围内的事务。 第四条 公司设立证券事务部作为负责管理信息披露事务的部门，董事会 秘书负责分管证券事务部。 第二章 董事会秘书的任职资格和任免 （四）取得上海证券交易所认可的董事会秘书资格证书和任职培训证明。 第六条 具有下列情形之一的人士不得担任董事会秘书： （一）《上市规则》第4.3 ...

上海润达医疗科技股份有限公司 内幕信息知情人登记管理制度 上海润达医疗科技股份有限公司 内幕信息知情人登记管理制度 （二〇二五年八月） 第一章 总 则 第一条 为规范上海润达医疗科技股份有限公司（以下简称"公司"）的内 幕信息管理，加强内幕信息保密工作，维护信息披露的"公开、公平、公正"原 则，保护广大投资者的合法权益，根据《中华人民共和国公司法》、《中华人民 共和国证券法》（以下简称"《证券法》"）、《上市公司信息披露管理办法》、 《上市公司监管指引第 5 号——上市公司内幕信息知情人登记管理制度》、《上 《上海证券交易所上市公司自律监管指引第 2 号 海证券交易所股票上市规则》、 ——信息披露事务管理》等有关法律、法规、规范性文件及《上海润达医疗科技 股份有限公司章程》（以下简称"《公司章程》"）、公司《信息披露管理制度》 的有关规定，特制定本制度。 第二条 公司董事会是内幕信息的管理机构，董事长是内幕信息保密工作的 主要负责人，董事会秘书负责办理公司内幕信息知情人的登记入档和报送事宜。 董事长与董事会秘书应当对内幕信息知情人档案的真实、准确和完整签署书面确 认意见。 第三条 公司证券事务部是信息披露管理 ...